Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael S Cookson

Showing results (191-200 of 219) with videos related to

Pageof 22
Sort By:
The Journal of Urology|January 16, 2007
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomesMichael S Cookson, Gunnar Aus, Arthur L Burnett, et al.
Plos One|May 17, 2012
Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferationDavid J DeGraff, Peter E Clark, Justin M Cates, et al.
The Journal of Urology|May 19, 2007
Guideline for the management of clinically localized prostate cancer: 2007 updateIan Thompson, James Brantley Thrasher, Gunnar Aus, et al.
The Journal of Urology|June 16, 2007
Erectile function outcome reporting after clinically localized prostate cancer treatmentArthur L Burnett, Gunnar Aus, Edith D Canby-Hagino, et al.
Nature Reviews. Urology|September 24, 2014
Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USASiamak Daneshmand, Anne K Schuckman, Bernard H Bochner, et al.
The American Journal of Pathology|April 25, 2015
Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder CancerOpal L Reddy, Justin M Cates, Lan L Gellert, et al.
The Journal of Urology|April 18, 2007
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot studyAdam S Kibel, Eli Rosenbaum, Michael W Kattan, et al.
The American Journal of Surgical Pathology|July 1, 2025
International Society of Urological Pathology Consensus Meeting 2024: Working Group 2 Preneoplastic and Precursor Lesions of the Urinary BladderMichelle R Downes, Antonio Lopez-Beltran, Roberto Contieri, et al.
BJU International|September 27, 2020
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinomaDavid D'Andrea, Surena Matin, Peter C Black, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 10, 2010
NCCN clinical practice guidelines in oncology: prostate cancer early detectionMark H Kawachi, Robert R Bahnson, Michael Barry, et al.
Pageof 22

Showing results (191-200 of 219) with videos related to

Sort By:
Pageof 22
The Journal of Urology|January 16, 2007
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomesMichael S Cookson, Gunnar Aus, Arthur L Burnett, et al.
Plos One|May 17, 2012
Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferationDavid J DeGraff, Peter E Clark, Justin M Cates, et al.
The Journal of Urology|May 19, 2007
Guideline for the management of clinically localized prostate cancer: 2007 updateIan Thompson, James Brantley Thrasher, Gunnar Aus, et al.
The Journal of Urology|June 16, 2007
Erectile function outcome reporting after clinically localized prostate cancer treatmentArthur L Burnett, Gunnar Aus, Edith D Canby-Hagino, et al.
Nature Reviews. Urology|September 24, 2014
Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USASiamak Daneshmand, Anne K Schuckman, Bernard H Bochner, et al.
The American Journal of Pathology|April 25, 2015
Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder CancerOpal L Reddy, Justin M Cates, Lan L Gellert, et al.
The Journal of Urology|April 18, 2007
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot studyAdam S Kibel, Eli Rosenbaum, Michael W Kattan, et al.
The American Journal of Surgical Pathology|July 1, 2025
International Society of Urological Pathology Consensus Meeting 2024: Working Group 2 Preneoplastic and Precursor Lesions of the Urinary BladderMichelle R Downes, Antonio Lopez-Beltran, Roberto Contieri, et al.
BJU International|September 27, 2020
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinomaDavid D'Andrea, Surena Matin, Peter C Black, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 10, 2010
NCCN clinical practice guidelines in oncology: prostate cancer early detectionMark H Kawachi, Robert R Bahnson, Michael Barry, et al.
Pageof 22